Neuraxis (NRXS) awards independent director 26K shares

Rhea-AI Filing Summary

Watkins Bradley Mitchell reported acquisition or exercise transactions in this Form 4 filing.

Neuraxis, Inc. (NRXS) reported that director Bradley Mitchell Watkins received an equity compensation grant of 26,073 shares of common stock on 2026-08-13. The shares were issued as compensation for services as an independent director, not as an open-market purchase, bringing his directly held stake to 72,408 shares.

Insider Trade Summary

Net Buyer: 26,073 shares

Net Buy 1 txn

Insider Watkins Bradley Mitchell

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	26,073	$6.28	$164K

Holdings After Transaction: Common Stock — 72,408 shares (Direct)

Footnotes (1)

1. F1. These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

Key Figures

Shares Granted: 26,073 shares Grant Value per Share: $6.28 per share Holdings After Transaction: 72,408 shares

3 metrics

Shares Granted 26,073 shares Common stock awarded to director on 2026-08-13 as compensation

Grant Value per Share $6.28 per share Reported transaction price for the 26,073-share director grant

Holdings After Transaction 72,408 shares Total common shares directly held by Bradley Mitchell Watkins after the grant

Key Terms

Form 4, independent director, equity compensation, Rule 10b5-1

4 terms

Form 4 regulatory

"Neuraxis (NRXS) Form 4 transaction was a compensation grant"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

independent director financial

"compensation for services as independent director of the Issuer"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

equity compensation financial

"received an equity compensation grant of 26,073 shares of common stock"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

Rule 10b5-1 regulatory

"The Form 4 indicates the Rule 10b5-1 checkbox is not marked"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did Neuraxis (NRXS) disclose for Bradley Mitchell Watkins?

Neuraxis disclosed that director Bradley Mitchell Watkins received a grant of 26,073 shares of common stock on 2026-08-13. The shares were issued as compensation for his services as an independent director, increasing his directly held position to 72,408 shares.

Was the Neuraxis (NRXS) Form 4 transaction an open-market buy or a compensation grant?

The reported transaction was a compensation grant, not an open-market purchase. Watkins received 26,073 shares of Neuraxis common stock as compensation for his services as an independent director, as indicated in the filing footnote.

At what price was the Neuraxis (NRXS) director share grant reported?

The grant to director Bradley Mitchell Watkins was reported at $6.28 per share. This per-share value is shown in the Form 4 for the 26,073 shares of common stock issued as compensation for his independent director services.

How many Neuraxis (NRXS) shares does Bradley Mitchell Watkins hold after this Form 4 transaction?

After the reported grant, Bradley Mitchell Watkins directly holds 72,408 shares of Neuraxis common stock. This total includes the newly issued 26,073 shares received on 2026-08-13 as compensation for his role as an independent director.

Does the Neuraxis (NRXS) Form 4 indicate trades under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, meaning the transaction was not affirmed as executed under a pre-arranged Rule 10b5-1 trading plan. It reflects a straightforward grant of shares as director compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 06:39 PM Accepted by SEC EDGAR 08/17/2026 - 06:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Watkins Bradley Mitchell

(Last) (First) (Middle)

11611 N. MERIDIAN ST, SUITE 330

(Street)

CARMEL INDIANA 46032

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2026		A		26,073(1)	A	$6.28(1)	72,408	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

	/s/ Bradley M. Watkins	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)